Key Highlights

  • Cash, cash equivalents and investments totaled $348.0 million at quarter end.
  • Cash runway is expected into the second half of 2028.
  • A Phase 1 monotherapy colorectal cancer data update is expected in January 2027.
  • Initial clinical data for CX-801 with KEYTRUDA in advanced melanoma is expected in the first half of 2027.

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a company focused on masked, conditionally activated biologics, reported third quarter 2026 financial results and provided a Business update. The company ended the quarter with $348.0 million in cash, cash equivalents and investments, which it said provides an expected cash runway into the second half of 2028. Chairman and Chief Executive Officer Sean McCarthy described Varseta-M as the company's central program.

Varseta-M and the Development Program

Varseta-M is an EpCAM-directed antibody drug conjugate with a topoisomerase-1 inhibitor payload, designed to improve treatment for colorectal and other cancers. The company said it is focused on rapidly advancing the monotherapy form toward a first registrational study in colorectal cancer. The development program is broadening, with an ongoing combination study with bevacizumab in metastatic colorectal cancer and new Phase 1 expansion cohorts in gastric and gastroesophageal junction cancer.

Management also described planned expansions into EpCAM-selected pancreatic ductal adenocarcinoma. The breadth of indications shows the company's effort to apply the platform across several tumor types, though early-stage programs of this kind typically require further data before a path to registration is set.

Data Milestones and Cash Position

A Phase 1 monotherapy metastatic colorectal cancer data update, including dose selection and a potential registrational strategy, is expected in January 2027. Initial clinical data for CX-801 in combination with KEYTRUDA in advanced melanoma are expected in the first half of 2027. Those two milestones define the near-term calendar for the company's clinical programs.

The cash position of $348.0 million, which the release said is expected to fund operations into the second half of 2028, gives the company time to reach the January and mid-2027 readouts.

Sector Context

Antibody drug conjugates and masked antibodies are an active area of oncology development, with many programs competing for similar tumor types. Early data in this category are often exploratory, and regulatory strategy depends heavily on the results of Phase 1 cohorts and on the choice of dose and patient population.

Risks and What to Watch Next

The company's programs carry clinical risk, since early-stage data may not support a registrational study, and timelines for both readouts could shift.

Final Takeaways

CytomX enters the next phase with $348.0 million in cash and investments and a runway into the second half of 2028. Its near-term value depends on the Varseta-M data milestones and on how the program moves toward a registrational study. The early-2027 readouts will provide the next evidence on whether the program's direction holds.